Source comparison
MOTS-c Study vs Traditional Metabolic Interventions — Research Comparison
MOTS-c (15mg 2×/week) AMPK activation, mitochondrial biogenesis, nuclear gene regulation +28% (Matsuda index) +11% VO2 max increase 4+ weeks Aging 2019, Nature Medicine 2020 Metformin (1000mg daily) AMPK activation, hepatic glucose output reduction +15–20% Min
This comparison does not assign a generated winner or score.
- MOTS-c (15mg 2×/week)
- AMPK activation, mitochondrial biogenesis, nuclear gene regulation
- +28% (Matsuda index)
- +11% VO2 max increase
- 4+ weeks
- Aging 2019, Nature Medicine 2020
- Metformin (1000mg daily)
- AMPK activation, hepatic glucose output reduction
- +15–20%
- Minimal direct effect
- Ceases upon discontinuation
- Diabetes Care 2012
- Resistance training (3×/week)
- Muscle hypertrophy, GLUT4 upregulation
- +25–30%
- +8–10% VO2 max
- 2–3 weeks detraining loss
- J Appl Physiol 2015
- Caloric restriction (25% deficit)
- Reduced oxidative stress, improved mitochondrial efficiency
- +20–25%
- Variable, often negative initially
- Rapid reversal upon refeeding
- Cell Metab 2018
- Berberine (1500mg daily)
- AMPK activation, gut microbiome modulation
- +18–22%
- No direct evidence
- Metabolism 2016
- Professional Assessment
- MOTS-c uniquely combines mitochondrial signalling with durable post-treatment effects. Unlike pharmacological AMPK activators that require continuous dosing, MOTS-c study evidence shows sustained metabolic reprogramming. Metformin's hepatic focus limits muscle-specific gains; training requires ongoing stimulus. MOTS-c bridges both with twice-weekly administration and weeks-long carryover. No other intervention matches this profile.